We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Allogene Therapeutics (ALLO - Free Report) . Shares have lost about 17.5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Allogene Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Allogene’s Q1 Earnings & Sales Top Estimates
Allogene incurred loss of 25 cents per share in first-quarter 2021, narrower than the Zacks Consensus Estimate of 48 cents as well as the year-ago quarter’s loss of 50 cents.
The company recorded revenues of $38.3 million, during the quarter, beating the Zacks Consensus Estimate of $24.5 million. It recorded the full amount per a license agreement with Allogene Overland. The company did not record any revenues in the year-ago quarter.
Quarter in Detail
Research & development (R&D) expenses were $55.2 million, up 31.3% from the year-ago quarter.
General and administrative (G&A) expenses increased 4.6% year over year to $16.4 million.
The company had $964.2 million in cash, cash equivalents and investments as of Mar 31, 2021, compared with $1 billion at the end of Dec 30, 2020
Maintains 2021 Guidance
Allogene maintained its previous guidance for operating expenses for 2021, which is expected to be between $300 million and $330 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
VGM Scores
At this time, Allogene Therapeutics has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions has been net zero. Notably, Allogene Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report?
A month has gone by since the last earnings report for Allogene Therapeutics (ALLO - Free Report) . Shares have lost about 17.5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Allogene Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Allogene’s Q1 Earnings & Sales Top Estimates
Allogene incurred loss of 25 cents per share in first-quarter 2021, narrower than the Zacks Consensus Estimate of 48 cents as well as the year-ago quarter’s loss of 50 cents.
The company recorded revenues of $38.3 million, during the quarter, beating the Zacks Consensus Estimate of $24.5 million. It recorded the full amount per a license agreement with Allogene Overland. The company did not record any revenues in the year-ago quarter.
Quarter in Detail
Research & development (R&D) expenses were $55.2 million, up 31.3% from the year-ago quarter.
General and administrative (G&A) expenses increased 4.6% year over year to $16.4 million.
The company had $964.2 million in cash, cash equivalents and investments as of Mar 31, 2021, compared with $1 billion at the end of Dec 30, 2020
Maintains 2021 Guidance
Allogene maintained its previous guidance for operating expenses for 2021, which is expected to be between $300 million and $330 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
VGM Scores
At this time, Allogene Therapeutics has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions has been net zero. Notably, Allogene Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.